newsfilter
← Latest News
GlobeNewswire·

Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent

  • Lisata Therapeutics announced positive preclinical data from licensing partner Catalent regarding the use of certepetide as a payload in the SMARTag ADC platform.
  • The data was presented at the 16th Annual World ADC San Diego Conference held November 3-6, 2025.
  • Results demonstrated that non-cytotoxic certepetide improved ADC efficacy & broadened cytotoxic payload distribution within the tumor microenvironment.
  • Catalent's Enhanced Conjugates innovation combines cytotoxic payloads with non-cytotoxic agents like certepetide to amplify efficacy without compromising safety.
  • Certepetide is an investigational iRGD cyclic peptide designed to activate a novel uptake pathway for enhanced penetration of anti-cancer drugs into solid tumors.
  • The drug has received U.S. Fast Track designation & Orphan Drug Designation for pancreatic cancer, plus Orphan Drug Designation for glioma & osteosarcoma.
  • Lisata's capital is projected to fund operations into the first quarter of 2027, supporting anticipated data milestones from ongoing clinical trials.